Licensing status

Publication and contact information


Nasopharyngeal cancer

Leukemia inhibitory factor (LIF); LIF receptor

Studies in mice and in patient samples suggest inhibiting LIF receptor signaling could help treat nasopharyngeal cancer. In primary nasopharyngeal tumors, LIF levels were higher than those in surrounding normal tissue. In patients with radiation-treated nasopharyngeal cancer, serum levels of LIF correlated with tumor recurrence. In human nasopharyngeal cell lines and xenograft mouse models, a soluble LIF decoy receptor decreased cell and tumor growth compared with vehicle. Ongoing work includes testing the efficacy of inhibiting LIF-receptor interactions in a Phase I trial in patients with radiation-treated nasopharyngeal cancer.

SciBX 7(1); doi:10.1038/scibx.2014.14
Published online Jan. 9, 2014

Patent application filed by Chang Gung University; available for licensing

Liu, S.-C. et al. J. Clin. Invest.; published online Nov. 25, 2013;
Contact: Yu-Sun Chang, Chang Gung University, Taoyuan, Taiwan
Contact: Ngan-Ming Tsang, Chang Gung Memorial Hospital,
Taoyuan, Taiwan